Search Results

You are looking at 171 - 180 of 377 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

toxicities included neutropenia (27%), elevated alanine aminotransferase level (13%), diarrhea (13%), and pneumonia (7%), and thrombocytopenia (6%). In a post hoc analysis, median PFS was 8 months for patients with POD within 12 months compared with 14 months

Full access

Abstracts From the NCCN 2024 Annual Conference

and 1 EGC pts; DL1 TALA 0.5 mg: 4 pts, DL2 TALA 0.75 mg: 5 pts, DL3 TALA 1 mg: 5 pts). We are currently enrolling patients in DL3. There are no major toxicity signals to this date. There was one dose-limiting toxicity (DLT, grade 4 neutropenia) in DL1

Full access

Part 2: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™

enrolled at dose level 1 (100 mg, qdx3, weekly), and 2 developed dose-limiting toxicities (DLTs). These DLTs included deep venous thrombosis/pulmonary embolism and grade IV febrile neutropenia in patient 1, and grade III febrile neutropenia and Clostridium

Full access

Small Cell Lung Cancer

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura QM Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry Jahan, Marianna Koczywas, Billy W. Loo Jr, Robert E. Merritt, Cesar A. Moran, Harvey B. Niell, Janis O’Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, Charles C. Williams Jr, Kristina Gregory, and Miranda Hughes

biopsies may be indicated in select patients with nucleated red blood cells on peripheral blood smear, neutropenia, or thrombocytopenia and no other evidence of metastatic disease. Bone marrow involvement as the only site of extensive-stage disease occurs

Full access

Adherence to Hematologic Hold Parameters in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions

Marina Stasenko, R. Kevin Reynolds, Carolyn Johnston, Melissa Brackman, Karen McLean, and Shitanshu Uppal

set at 50 × 10 9 /L ( Table 1 ). The frequency of grade 3 and 4 thrombocytopenia and neutropenia were similar in the dose-dense and conventional chemotherapy groups in the studies and, because of hold parameter modifications, the JGOG trial noted that

Full access

Updates to the Management of Chronic Lymphocytic Leukemia

William G. Wierda

the German CLL Study Group comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia: results on survival, progression-free survival, delayed neutropenias and

Full access

Management of Dermatologic Toxicities

Mario E. Lacouture

70%, versus reactive treatment, and also reduced pruritus, secondary infections, and paronychia as well as non-dermatologic toxicities grade 3 or greater (diarrhea, neutropenia, etc). 4 “Importantly, prophylaxis does not negate the beneficial anti

Full access

Brentuximab in the Treatment of CD30-Positive Enteropathy-Associated T-Cell Lymphoma

Waleed F. Khalaf, Meghan E. Caldwell, and Nishitha Reddy

his baseline grade 2 neuropathy. He developed mild leukopenia without neutropenia. At his 9-month follow-up, the patient continued to show disease remission. Discussion EATL is a rare gastrointestinal lymphoma that accounts for fewer than 1% of

Full access

New Developments in the Treatment of Castration-Resistant Prostate Cancer

Celestia S. Higano

than those in the mitoxantrone group (57% vs 39%). The most common significant adverse events (≥ grade 3) for cabazitaxel were neutropenia and diarrhea. “Because of the toxicity, some people have not been too enthused about using cabazitaxel,” stated

Full access

Is Observation Dead in Follicular Lymphoma? Still Appropriate

Caron A. Jacobson and Arnold S. Freedman

deterioration in their mental adjustment to, or ability to cope with, their illness. No difference in histologic transformation or OS was observed. Finally, 12 grade 3/4 adverse events were seen in the patients who received rituximab, including neutropenia